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Aim: To investigate the effect of intermittent pneumatic compression (IPC) pumps on upper extremity impairments in breast cancerrelated lymphedema.
Materials and methods: Twenty-five patients with lymphedema were randomized into 2 groups. For 3 weeks, the pneumatic compression
group (n = 12) underwent a treatment program including skin care, compression bandage, exercise therapy, manual lymph drainage
(MLD), and IPC. The control group (n = 13) participated in the same program, but without IPC. The range of motion (ROM) of the
upper extremities was measured with goniometry, and dysfunction of the shoulder was assessed with the Constant-Murley scale.
Results: Significant improvements were observed in the ROM of the shoulder when we evaluated pre- and posttreatment values within
both groups, and the improvements were still significant at 1-month follow-up. Likewise, we found significant differences in the visual
analogue scale (VAS) and the Constant-Murley scores in both groups when we compared pre-treatment and posttreatment values, and
significant differences were still present at 1-month follow-up. However, there were no significant differences between the groups in the
upper limb’s ROM, the VAS, or the Constant-Murley scale after the therapy or at the 1-month follow-up.
Conclusion: Upper extremity impairments may improve with conservative treatment of lymphedema. However, the addition of IPC to
the therapy may not provide any additional benefit for upper extremity impairments.
Key words: Upper limb, lymphedema, pneumatic compression, manual lymph drainage, rehabilitation

1. Introduction
Breast cancer has been the most common form of cancer in
women (1), but its incidence has decreased with increasing
diagnosis and treatment options in the last few years (2,3).
However, illness-induced functional impairment still
constitutes a problem.
Breast cancer patients develop some complications
because of both the nature of the cancer itself and the
treatment of the cancer, including cosmetic, psychological,
and physical problems, such as dysfunction of the shoulder
and lymphedema (4–6). Daily activities, such as reaching
above the head or moving one’s hands behind one’s back
for putting on clothing, become more difficult for patients.
The reported prevalence of impairments in the shoulder’s
range of motion (ROM) has been reported to vary from
1% to 67% (7). For example, the shoulder’s ROM was
reported to be limited in up to 45% of patients who
underwent sentinel node biopsy and in 86% of patients
who underwent axillary dissection (8). Lymphedema can
* Correspondence: drhulyauzkeser@gmail.com

be defined as an abnormal accumulation of interstitial fluid
that occurs primarily as a consequence of malformation
or acquired disruption of the lymphatic circulation
system (9). Breast cancer-related lymphedema refers to
a swelling of the arm caused by damage to the axillary
lymph drainage routes during breast cancer treatment
(10). Lymphedema is one of the predominant physical
sequelae, and it has an impact on the physical function of
the shoulder; shoulder impairment is higher in patients
with lymphedema than in patients without lymphedema
(11). Currently, complex decongestive physical therapy is
accepted as an international standard treatment approach
for the treatment of lymphedema (12). Such treatment
occurs in combination with skin care, manual lymph
drainage (MLD), compression bandages, compression
garments, and exercises. The application of intermittent
pneumatic compression (IPC) as part of a complex
decongestive physical therapy remains controversial (13).
MLD is a massage technique that is performed from

99

UZKESER and KARATAY / Turk J Med Sci

distal to proximal directions (14). IPC, which involves
gradual pressure gradients on the lymph vessels, helps
the lymph flow (15). Of studies regarding the use of IPC
for reducing lymphedema (13,15–17), we found only one
study that compared the effect of MLD and IPC on arm
mobility in patients with lymphedema (17). To the best
of our knowledge, our study is the first controlled trial
investigating the effect of IPC on functional limitations of
the upper limbs.
2. Materials and methods
The study was performed at the Physical Medicine and
Rehabilitation Department of Atatürk University Faculty
of Medicine and Erzurum Research and Training Hospital.
Twenty-five patients with upper extremity lymphedema
following mastectomy with no history of physical therapy
were enrolled in this randomized, controlled trial. All the
participants were informed of the study protocol and, in
accordance with the Declaration of Helsinki, their written
informed consent was obtained.
Patients who had a history of unilateral lymphedema
for at least 3 months and no history of physical therapy
were recruited. Patients who had bilateral lymphedema,
current metastases, continuing radiotherapy, elephantiasis,
infection, lymphangiosis carcinomatosa, cellulitis, venous
thrombosis, or congestive heart failure, or who were using
any medications that affect the body fluid or the electrolyte
balance were excluded.
The patients were sequentially randomized into 2
groups: a pneumatic compression group and a control
group. The treatment of the pneumatic compression
group (n = 12) included skin care, MLD, IPC (MARK III
Plus MK400 model, 6 outlets), compression bandages,
and exercises; the IPC was applied after the MLD. The
control group (n =13) underwent the same program, but
without IPC. Both groups were treated 5 times per week
for 3 weeks, for a total of 15 sessions. After the therapy,
the patients were instructed to continue the exercises and
to use their compression bandages. The same physician
assessed the patients initially, after the therapy, and 1
month after completing the therapy. The physician who
assessed the patients was blind to the treatment groups.
Demographic features of the patients, including age,
number of rounds of chemotherapy and radiotherapy,
duration of lymphedema, and number of lymph node
dissections, were recorded. Lymphedema was measured
with the water-immersion method, which is still the gold
standard (18). The volumes of the affected and unaffected
limbs were calculated, and the difference between these 2
values was recorded. Lymphedema was defined as more
than a 10% volume difference between the arms.
Goniometry was used to measure the ROM of the
upper extremities. The shoulder’s flexion, abduction,
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external rotation, and internal rotation; the elbow’s flexion
and extension; and the wrist’s flexion and extension were
all measured according to the neutral-zero method.
The dysfunction of the shoulder was assessed with
the Constant-Murley scale, which was designed to assess
upper extremity disability (19). This scale evaluates pain,
activities of daily living (ADL), working conditions, sleep
comfort, ability to use the arm, the shoulder’s ROM, and
muscle strength. Pain was evaluated on a 0–15 point scale
(none: 15 points, mild: 10 points, moderate: 5 points, and
severe: 0 points). The ADL score is divided into 4 items:
sleeping: 2 points; levels of activity: 10 points; hobby/
sport: 4 points; positioning of the hand: 10 points. The
ROM is evaluated in terms of the flexion, abduction, and
internal and external rotation of the shoulders, with 10
points assigned to each. Finally, strength is evaluated as
pounds of pull that the patient can resist in abduction, to
a maximum of 25 points. The total possible score is 100
points (pain: 15 points; ADL: 20 points; ROM: 40 points;
and strength: 25 points), indicating an asymptomatic and
healthy person, while the worst score is 0 points.
In addition, the patients were questioned about arm
pain complaints. Pain was measured by the visual analogue
scale (VAS) of 0–100 mm, ranging from no pain to very
severe pain.
Statistical analysis was performed using SPSS version
15.0 for Windows (SPSS Inc., Chicago, IL, USA).
Differences between the groups were tested using the
Mann–Whitney U test. The repeated measures ANOVA
test was used to determine angle changes over time and
to examine the differences between the treatment groups.
The Friedman analysis of variance was used when the
sphericity assumption was not met. Wilcoxon’s test was
used to evaluate pre- and posttreatment values within
the groups. Correlation analysis between the parameters
was performed by Pearson’s correlation test. The level of
statistical significance was set at P < 0.05.
3. Results
The demographic variables, such as age, body mass
index, duration of lymphedema, number of lymph node
dissections, and lymphedema volume were similar
between the 2 groups (P > 0.05) (Table 1). There were
no significant differences in the shoulder’s flexion/
abduction, the shoulder’s external/internal rotation, the
elbow’s flexion/extension, the wrist’s flexion/extension,
the Constant-Murley scale, or the VAS score between the 2
groups before the treatment (P > 0.05).
When we examined the correlation between the
lymphedema volume and the upper limb’s ROM, we found
that only flexion and internal rotation of the shoulder
were correlated with the lymphedema volume (P < 0.04,
P < 0.01, respectively). However, we did not find any
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Table 1. Demographic characteristics of patients in both groups [median (minimum–maximum)].
Control group

Pneumatic compression group

P

Age (years)

54 (37–65)

56 (43–75)

>0.05

Weight (kg)

78 (61–93)

77 (60–91)

>0.05

Height (cm)

157 (140–165)

158 (140–165)

>0.05

BMI (kg/m2)

32.7 (26–41)

31.7 (23.8–40.8)

>0.05

10 (8–23)

11 (3–22)

>0.05

580 (180–1780)

850 (260–1560)

>0.05

Number of lymph node dissections
Volume difference (cm )
3

BMI: Body mass index

correlation between the lymphedema volume and the
Constant-Murley scale or the VAS. In addition, we tested
the correlation between the Constant-Murley scale and
movement restrictions of the upper limbs, and there were
significant correlations between the Constant-Murley
scale and the shoulder’s ROM. The correlations for the
ROM of the shoulder had P < 0.001 values.
In the pneumatic compression group, a significant
improvement was observed in the ROM of the shoulder,
except for external rotation, when we evaluated pre- and
posttreatment values (Table 2). This significant difference

was also seen at the 1-month follow-up after the therapy
(Table 2). In addition, the VAS and Constant-Murley
scores were decreased after the therapy in the pneumatic
compression group (P = 0.01, P = 0.002, respectively), and
those decreases continued at the 1-month follow-up when
compared to the baseline (P = 0.01, P = 0.002, respectively).
In the control group, significant improvements were
detected after the treatment in the ROM of the shoulder.
These improvements were also observed 1 month later
(Table 3). Significant differences were observed in the VAS
and the Constant-Murley scores pre- and posttreatment in

Table 2. Comparison of measurements pre- and posttreatment and 1 month after in the pneumatic compression group [median
(minimum–maximum)].
Pneumatic compression group

Pre-treatment

Posttreatment

After 1 month

P1

P2

Shoulder flexion

152 (45–180)

170 (50–180)

170 (50–180)

0.018

0.017

Shoulder abduction

130 (50–180)

165 (50–180)

165 (50–180)

0.017

0.018

Shoulder internal rotation

57 (20–80)

70 (20–80)

70 (20–80)

0.01

0.01

Shoulder external rotation

90 (20–90)

90 (20–90)

90 (20–90)

ns

ns

150 (150–150)

150 (150–150)

150 (150–150)

ns

ns

0 (0–0)

0 (0–0)

0 (0–0)

ns

ns

Wrist flexion

80 (0–80)

80 (80–80)

80 (80–80)

ns

ns

Wrist extension

70 (70–70)

70 (70–70)

70 (70–70)

ns

ns

Constant-Murley

54 (2–63)

59 (2–63)

59 (10–65)

0.002

0.002

VAS

20 (0–100)

5 (0–70)

0 (0–70)

0.01

0.01

Elbow flexion
Elbow extension

VAS: Visual analogue scale
P 1: P value of pre- and posttreatment
P 2: P value of pretreatment and 1 month after
ns: not significant
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Table 3. Comparison of measurements pre- and posttreatment and 1 month after in the control group [median (minimum–maximum)].
Control group

Pre-treatment

Posttreatment

After 1 month

P1

P2

Shoulder flexion

160 (80–180)

160 (80–180)

170 (110–180)

0.018

0.018

Shoulder abduction

160 (10–180)

170 (110–180)

170 (105–180)

0.018

0.017

Shoulder internal rotation

60 (40–80)

80 (40–80)

80 (40–80)

0.008

0.01

Shoulder external rotation

75 (20–90)

90 (20–90)

90 (20–90)

0.041

0.042

150 (150–150)

150 (150–150)

150 (150–150)

0 (0–0)

0 (0–0)

0 (0–0)

ns

ns

Wrist flexion

80 (40–80)

80 (45–80)

80 (45–80)

ns

ns

Wrist extension

70 (55–70)

70 (70–70)

70 (70–70)

ns

ns

Constant-Murley

52 (10–63)

57 (23–65)

57 (23–65)

0.001

0.001

VAS

40 (0–70)

20 (0–50)

10 (0–50)

0.004

0.004

Elbow flexion
Elbow extension

ns

ns

VAS: Visual analogue scale
P1: P value of pre- and posttreatment
P2: P value of pretreatment and 1 month after
ns: not significant

the control group (P = 0.004, P = 0.001, respectively), and
those improvements continued at the 1-month follow-up
(P = 0.004, P = 0.001, respectively).
Comparing the 2 groups, there were no significant
differences in the upper limb’s ROM, the VAS, or the
Constant-Murley scale after the therapy or 1 month after
completing the therapy. However, there were significant
improvements immediately after the therapy and 1 month
after completing the therapy in both groups.
4. Discussion
Breast cancer-related lymphedema may cause upper limb
ROM impairments because of scar tissue formation,
radiation-induced fibrosis, and protective posturing
due to pain or disuse. Few studies in the literature have
investigated the association among upper extremity
limitations, treatment, and disability in patients with
breast cancer (20,21). Therefore, we aimed to evaluate the
functional limitations of the upper limbs and the efficacy
of IPC in secondary breast lymphedema. This is the first
controlled study to investigate the efficacy of IPC for
functional limitations of the upper limbs. Previous studies
of the ability of IPC pumps to reduce lymphedema have
reported different results (16,22,23). Dini et al. used IPC
pumps at a pressure of 60 mmHg, as we did. They reported
that IPC has a limited clinical role in the treatment of
postmastectomy lymphedema. However, they did not
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evaluate the functional limitations of the upper limbs. In
our study, we found that IPC and MLD were both effective
for improving the ROM of the upper limbs (mainly the
shoulder), ADL, and pain.
Besides the treatment modalities, we examined the
correlation between the lymphedema volume and quality
of life. We assessed ADL using the Constant-Murley scale,
and we did not find any correlation between lymphedema
volumes. However, we found a correlation between
the lymphedema volume and movement restriction of
the shoulder. Nesvold et al. conducted a study on the
relationship between shoulder problems and quality of life
in breast cancer (24), using the SF-36 to evaluate quality of
life; our results were similar to theirs.
To the best of our knowledge, one study in the literature
has compared treatment modalities on shoulder function
in patients with lymphedema. Johansson et al. compared
MLD and IPC in 28 patients over 2 weeks (17). They
applied MLD to one group and IPC to the other group,
and they found that treatment with MLD or IPC did not
change the arm’s mobility. Those findings were contrary to
our results, because we observed significant improvements
in the shoulder’s ROM. Johansson et al.’s study did not
have an active or a placebo control group, whereas our
study included an MLD control group. On the other hand,
our study also had some limitations, such as a lack of longterm follow-ups and a small sample size.
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In conclusion, complex decongestive physical therapy
seems to be effective in both lymphedema reduction and
in improvement of upper extremity impairments, and
the addition of IPC to the therapy may not provide any
additional benefit. To the contrary, IPC may increase the

total cost and time. Further controlled studies involving a
larger number of patients over a longer period are needed
to investigate the effects of IPC on functional limitations
of the upper limbs.
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